by • July 18, 2016 • No Comments
Sleep apnoea devices developer Oventus Medical has listed on the Australian Securities Exchange (ASX) after raising AU$12 million.
In partnership with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Oventus has been developing for the last two-and-a-half years the O2Vent, a customisable, 3D-printed titanium mouthguard created ensure optimal airflow, while reduce the impacts of snoring for sleep apnoea sufferers.
Latest Australian newsSpectrum sharing key to IoT, 5G: ACMANSW government offering AU$20,000 compensation grants to taxi drivers thanks to UberAustralia wants to steal US patents: US Senate Finance chairAustralian Privacy Commissioner pokes Niantic for building Pokémon Go catch it allTelstra strengthens enterprise mobility offering with MSC Mobility acquisition
The first prototype of the O2Vent, which accomplished successful clinical trials, was 3D-printed via CSIRO’s 3D printing facility, Lab22.
“This allowed us to explore new and new making techniques with a reduced investment risk,” Oventus founder Dr Chris Hart said.
“Using 3D-printing to make the O2Vent sleep apnoea devices offered us massive advantages over traditional making methods which include speed and cost.
“This partnership has created us globally competitive.”
The Brisbane-based company said the raised capital can be utilized to commercialise and donate its O2Vent device, which succeded in Food and Drug Administration approval in the United States in April this year.
Lab22 was previously responsible for helping Melbourne-based medical device company Anatomics 3D-print a titanium sternum and rib impact for a 54-year-old Spanish man. The patient needed his sternum and a portion of his rib cage replaced due to a chest wall sarcoma, a type of tumour which grows in and around the rib cage. The CSIRO said at the time the patient’s surgical team knew the surgery may be complex due to the complex geometries involved in the chest cavity, and decided the customisable 3D-printed sternum and rib cage was the most version.
Once the prosthesis was deplete it was sent to Spain and implanted into the patient. According to the CSIRO, 12 days after the surgery the patient was discharged and recovered well.
Last September, the Australian Department for Industry and Science in partnership with IP Australia released a toolkit for collaboration, meant for use by businesses, in particular tiny to medium enterprises (SMEs), public funded organisations, and individual researchers intending to undertake collaborative ventures.
The toolkit collaboration outlined practices on how to increase the effectiveness of collaboration, strengthen relationships for ongoing collaboration, and tackle intellectual property.
by admin • March 5, 2017
by admin • November 28, 2016
by admin • November 28, 2016